Ben George, MD
Medical Oncology · Rochester, MNNPI 1295930519
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Foundation Medicine, Inc. at 33.3% of the total. Among medical oncology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 354 payments — averaging $1634.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Foundation Medicine, Inc.$193K
- Taiho Oncology, Inc.$130K
- Ipsen Biopharmaceuticals, Inc$64K
- Astellas Pharma US Inc$50K
- AstraZeneca$41K
- E.r. Squibb & Sons, L.L.C.$34K
- plus $67K from 22 others
Across 676 payments — averaging $7352.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$1.4M
- E.r. Squibb & Sons, L.L.C.$896K
- Roche Products Limited$778K
- Genentech, Inc.$696K
- Boehringer Ingelheim International GmbH$692K
- Pfizer$152K
- plus $401K from 13 others
What the payments were for
- Consulting fees$224,85439%
- Speaking & faculty fees$298,53152%
- Travel & lodging$48,6668%
- Food & beverage$6,3571%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Foundation Medicine, Inc. | 48 | $192,604 |
| Taiho Oncology, Inc. | 85 | $129,678 |
| Ipsen Biopharmaceuticals, Inc | 61 | $63,924 |
| Astellas Pharma US Inc | 39 | $50,411 |
| AstraZeneca | 26 | $41,153 |
| E.r. Squibb & Sons, L.L.C. | 30 | $33,866 |
| F. Hoffmann-la Roche AG | 8 | $11,681 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $9,075 |
| Boston Scientific | 4 | $9,063 |
| Corcept Therapeutics | 7 | $6,676 |
| Bristol Myers Squibb | 6 | $6,616 |
| Roche Diagnostics International Ltd | 4 | $4,242 |
| Beone Medicines USA, Inc. | 1 | $3,200 |
| Amgen | 2 | $2,845 |
| Boehringer Ingelheim International GmbH | 4 | $2,746 |
| Legend Biotech USA Inc. | 1 | $2,555 |
| Roche Products Limited | 3 | $1,758 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $1,511 |
| Array Biopharma Inc | 2 | $1,330 |
| Exelixis Inc. | 3 | $1,034 |
| Terumo Medical Corporation | 2 | $930 |
| Daiichi Sankyo Inc. | 1 | $900 |
| Tempus AI, Inc | 2 | $243 |
| Genentech USA, Inc. | 2 | $191 |
| Sirtex Medical Inc | 1 | $141 |
| Seagen Inc. | 1 | $99 |
| Ionis Pharmaceuticals, Inc. | 1 | $20 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONONE CDX$186,167
- Lonsurf$128,719
- ONIVYDE$61,366
- Vyloy$43,330
- IMFINZI$40,624
- FOUNDATIONONE LIQUID$39,800
- FOUNDATIONFOCUS$39,800
- FOUNDATIONONE HEME$39,800
- FOUNDATIONONE$39,800
- FRUZAQLA$8,999
- Abraxane$6,400
- TheraSphere Administration Set$6,250
- SOMATULINE DEPOT$4,360
- TEVIMBRA$3,200
- THERASPHERE$2,813
- Avastin$1,758
- TECENTRIQ$1,758
- BRAFTOVI$1,330
- Enhertu$900
- Cabometyx$566
How this compares
$578,506 in reported general payments places this provider in the 95th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 65 | $878 |
| Dexamethasone | 45 | $365 |
| Prochlorperazine Maleate | 17 | $154 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Rochester
- Amit MahipalRochester$746K
- Alton SartorRochester$688K
- Elisabeth HeathRochester$236K
- Matthew GoetzRochester$136K
- Thorvardur HalfdanarsonRochester$86K
- Harry YoonRochester$69K
- Karthik GiridharRochester$66K
- Joleen HubbardRochester$59K
- Lionel Aurelien Kankeu FonkouaRochester$58K
- Kaushal ParikhRochester$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.